Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. In clinical research it slows gastric emptying, increases satiety signalling, and improves insulin secretion in a glucose-dependent manner. Research protocols typically use once-weekly subcutaneous administration because of its extended half-life.
Research vials are commonly supplied as lyophilized powder (e.g. 5 mg). Exact titration schedules vary by study design; the table below reflects commonly discussed research starting ranges, not a prescription.